Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Frank Fraioli

Family Medicine Smithfield, RI Doctor of Osteopathy

NPI 1386627248 CMS profile 107722

41 Sanderson Rd, Suite 206, Smithfield, RI 02917

Open in the dashboard

General payments

$10,428

550 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Frank Fraioli of Smithfield, RI is reported in the CMS Open Payments database as having received $10,428 across 550 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $43 2
2022 General $287 13
2021 General $3,779 185
2020 General $2,499 141
2019 General $3,819 209

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Fraioli
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Frank Fraioli were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Frank Fraioli Family Medicine median Middle half National median
2019 $3,819 $150 $41–$543 $163
2020 $2,499 $120 $32–$415 $114
2021 $3,779 $137 $35–$551 $132
2022 $287 $137 $37–$512 $149
2023 $43 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $1,423 63 payments
  2. AstraZeneca Pharmaceuticals LP $1,062 61 payments
  3. Pfizer Inc. $1,018 76 payments
  4. Novo Nordisk Inc $989 45 payments
  5. AbbVie, Inc. $763 39 payments
  6. GlaxoSmithKline, LLC. $718 47 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $586 27 payments
  8. Nestle HealthCare Nutrition Inc. $328 15 payments
  9. Allergan Inc. $316 14 payments
  10. Amarin Pharma Inc. $304 12 payments
  11. Other $2,922 151 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $10,413 549 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2023
  1. XARELTO $1,402 62 payments
  2. FARXIGA $595 28 payments
  3. RYBELSUS $515 22 payments
  4. Ozempic $487 29 payments
  5. TRELEGY ELLIPTA $449 26 payments
  6. COLOGUARD $440 37 payments
  7. INVOKANA $381 23 payments
  8. ZENPEP $328 15 payments
  9. ELIQUIS $282 19 payments
  10. JARDIANCE $270 14 payments
  11. Other $7,816 458 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Family Practice: 1,826

Drug cost

$297

Median for Family Practice: $120,094

Branded share of claims

0%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 12 $297

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

550 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record